Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: Single center experience with telaprevir-based triple therapy

Zeitschrift fur Gastroenterologie

Volumn 52, Issue 1, 2014, Pages 27-34

  Werner, C R ^a   Egetemeyr, D P ^a   Nadalin, S ^a   Konigsrainer A ^a   Malek, N P ^a   Lauer, U M ^a   Berg, C P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

fibrosing cholestatic hepatitis; hepatitis C; liver transplantation; side effects; SVR; telaprevir

Indexed keywords

CREATININE; CYCLOSPORIN A; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TELAPREVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BACTERIAL PNEUMONIA; BLOOD TRANSFUSION; CANDIDIASIS; CHOLESTATIC HEPATITIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GENOTYPE; GRAFT FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HERPETIC STOMATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A (H1N1); INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; KIDNEY INJURY; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MIXED INFECTION; NOROVIRUS INFECTION; PALLIATIVE THERAPY; RECURRENT INFECTION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIREMIA; VIRUS ACTIVATION; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84892602582     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1356345     Document Type: Article

References (30)

1. Rockville M. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 2011
2. Crespo G., Marino Z., Navasa M. et al. Viral hepatitis in liver transplantation. Gastroenterology: 2012; 142 06 1373 1383
3. Terrault N. Liver transplantation in the setting of chronic HCV. Best practice & research Clinical gastroenterology: 2012; 26 04 531 548 PubMed PMID: 23199510. Epub 2012/12/04.
4. Berenguer M., Prieto M., Rayon J. M. et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology: 2000; 32 4 Pt 1 852 858 PubMed PMID: 11003634. Epub 2000/09/26.
5. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. Journal of hepatology: 2008; 49 02 274 287 PubMed PMID: 18571272.
6. Ponziani F. R., Gasbarrini A., Pompili M. et al. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplantation proceedings: 2011; 43 01 291 295 PubMed PMID: 21335208. Epub 2011/02/22.
7. Zimmermann T., Bocher W. O., Biesterfeld S. et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int: 2007; 20 07 583 590 PubMed PMID: 17433090. Epub 2007/04/17. (Pubitemid 46872748)
8. Castells L., Vargas V., Allende H. et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of hepatology: 2005; 43 01 53 59 PubMed PMID: 15876467. Epub 2005/05/07. (Pubitemid 40805272)
9. Ghany M. G., Nelson D. R., Strader D. B. et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology: 2011; 54 04 1433 1444 PubMed PMID: 21898493. Pubmed Central PMCID: 3229841. Epub 2011/09/08.
10. Sarrazin C., Berg T., Cornberg M. et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Zeitschrift fur Gastroenterologie: 2012; 50 01 57 72 PubMed PMID: 22222799. Epub 2012/01/10. Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir. ger.
11. Sarrazin C., Hezode C., Zeuzem S. et al. Antiviral strategies in hepatitis C virus infection. Journal of hepatology: 2012; 56 01 S88 S100 PubMed PMID: 22300469. Epub 2012/02/04.
12. Jacobson I. M., McHutchison J. G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine: 2011; 364 25 2405 2416 PubMed PMID: 21696307. Epub 2011/06/24.
13. Sherman K. E., Flamm S. L., Afdhal N. H. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. The New England journal of medicine: 2011; 365 11 1014 1024 PubMed PMID: 21916639. Epub 2011/09/16.
14. Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection. The New England journal of medicine: 2011; 364 25 2417 2428 PubMed PMID: 21696308. Epub 2011/06/24.
15. Bacon B. R., Gordon S. C., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. The New England journal of medicine: 2011; 364 13 1207 1217 PubMed PMID: 21449784. Pubmed Central PMCID: 3153125. Epub 2011/04/01.
16. Poordad F., McCone Jr.J. et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England journal of medicine: 2011; 364 13 1195 1206 PubMed PMID: 21449783. Epub 2011/04/01.
17. Garg V., van Heeswijk R., Lee J. E. et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology: 2011; 54 01 20 27 PubMed PMID: 21618566. Epub 2011/05/28.
18. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology: 2011; 54 01 3 5 PubMed PMID: 21710471. Epub 2011/06/29.
19. Werner C. R., Egetemeyr D. P., Lauer U. M. et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society: 2012; 18 12 1464 1470 PubMed PMID: 22941516. Epub 2012/09/04.
20. Coilly A., Roche B., Botta-Fridlund D. et al. Efficacy and Safety of Protease Inhibitors for severe Hepatitis C Recurrence after Liver Transplantation: a first multicentric Experience. J Hepatol: 2012; 56 02 S21 S44
21. Pungpapong S., Aqel B. A., Koning L. et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society: 2013; 19 07 690 700 PubMed PMID: 23696372.
22. Herzer K., Papadopoulos-Kohn A., Timm J. et al. HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy. Dtsch Med Wochenschr: 2013; 138 36 1759 1764 PubMed PMID: 24002874. Epub 2013/09/05. HCV-Reinfektion nach Lebertransplantation. Management und erste Ergebnisse mit der Telaprevir-basierten Triple-Therapie.
23. Verna E. C., Burton J. R., O'Leary J. G. et al. A Multicenter Study of Protease Inhibitor-Triple Therapy in HCV-Infected Liver Transplant Recipients: Report from the CRUSH-C Group (Abstract #23). Journal of hepatology: 2013; 58 S10
24. Coilly A., Roche B., Dumortier J. et al. Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver Transplantation, a Multicenter Experience. J Hepatol: 2013; PubMed PMID: 23994384.
25. Werner C. R., Egetemeyr D. P., Lauer U. M. et al. Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results. PLoS One: 2013; 8 11 e80528. PubMed PMID: 24265827. Epub 2013/11/23.
26. Werner C. R., Franz C., Egetemeyr D. P. et al. Efficacy and safety of Telaprevir (TVR) triple therapy in a real-life cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat: 2013; in press.
27. Berenguer M., Palau A., Aguilera V. et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons: 2008; 8 03 679 687 PubMed PMID: 18294165. Epub 2008/02/26. (Pubitemid 351287553)
28. Gane E. J., Stedman C. A., Hyland R. H. et al. Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology 2013 Nov 18. pii: S0016-5085(13)01653
29. Gane E. J., Stedman C. A., Hyland R. H. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. The New England journal of medicine: 2013; 368 01 34 44 PubMed PMID: 23281974.
30. Lawitz E., Gane E. J. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England journal of medicine: 2013; 369 07 678 679 PubMed PMID: 23944316.